scholarly article | Q13442814 |
P50 | author | Armin Zebisch | Q62554773 |
Gerald Hoefler | Q41609985 | ||
Heinz Sill | Q42374295 | ||
P2093 | author name string | J Troppmair | |
M Haller | |||
T Goebel | |||
K Hiden | |||
P2860 | cites work | Acute myeloid leukemia in an adult Noonan syndrome patient with PTPN11 mutation. | Q46521681 |
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation | Q46632829 | ||
Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. | Q51926460 | ||
Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. | Q54539796 | ||
Are mouthwashes a reliable source of constitutional DNA in patients with leukemia? | Q57636781 | ||
Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1 | Q73182784 | ||
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation | Q24548297 | ||
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy | Q27865193 | ||
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP | Q28144497 | ||
Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive) | Q28238801 | ||
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia | Q28305210 | ||
Noonan syndrome and related disorders: genetics and pathogenesis | Q34560418 | ||
Germline gain-of-function mutations in RAF1 cause Noonan syndrome | Q34644154 | ||
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. | Q35080478 | ||
Mechanisms of therapy-related carcinogenesis | Q36315585 | ||
Signaling through RAS-RAF-MEK-ERK: from basics to bedside. | Q36754537 | ||
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility | Q36787577 | ||
Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia | Q36835902 | ||
Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells | Q36996036 | ||
Genetics of therapy-related myelodysplasia and acute myeloid leukemia | Q37058777 | ||
Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer | Q39970092 | ||
Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis | Q40358926 | ||
RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis | Q40591753 | ||
The risk of developing second cancers among survivors of childhood soft tissue sarcoma | Q43523794 | ||
Therapy-induced malignant neoplasms in Nf1 mutant mice. | Q46001683 | ||
Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells | Q46395700 | ||
P433 | issue | 6 | |
P921 | main subject | leukemia | Q29496 |
P304 | page(s) | 1049-1053 | |
P577 | publication date | 2009-04-09 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations | |
P478 | volume | 23 |